Article Details
Retrieved on: 2025-03-05 01:49:22
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the FDA approval of denosumab biosimilars, Stoboclo and Osenvelt, highlighting their role in treating osteoporosis and bone loss, aligning with epidemiology by expanding therapeutic options for managing bone-related conditions.
Article found on: www.ajmc.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here